During the past few years, CRYOPDP has been actively acquiring companies with interesting new technologies, competencies, and with similar principles as ours to enhance our capacity to keep delivering live-saving goods around the world.   

CRYOPDP has just acquired Polar Expres, a Clinical, Cell & Gene, and Biopharma logistics provider market leader fully dedicated to clinical trial logistics. Based in Spain, Polar Express has established customers, in the public and private sectors in Europe.

Polar Expres expertise in Clinical, Cell & Gene and Biomedical logistics and unique services enable CRYOPDP to expand its footprint in one of the top geographical markets in the Clinical Research area and also in the dynamic and growing Cell & Gene sector. Therefore, this opportunity will allow CRYOPDP to expand its temperature-controlled logistics & supply chain solutions by answering the demands of the life science and healthcare communities.

By incorporating Spain into CRYOPDP’s network, Polar Expres team will contribute to enhance our capacity to keep delivering live-saving goods worldwide. 

“Polar Expres represents a significant opportunity for CRYOPDP in the south of Europe and Europe in general. With a solid and well-established reputation, Polar expres will allow us to reinforce our position in the Biopharma and Cell & Gene market, expanding our opportunities among Clinical Trials communities.” said Cedric Picaud, Chief Executive Officer of CRYOPDP.

Jerrell Shelton, CEO of Cryoport, said, "The acquisition of Polar Expres will expand our coverage in Europe and enable us to provide end-to-end solutions to both global and local customers in Spain.  Spain is a highly strategic and key area for pharma/biopharma clinical trials and a growing number of cell & gene activities.  This tactical acquisition will provide strategic impact for CRYOPDP as requests for local, on-the-ground operations in Spain continues from many of our clients, as well as from potential new clients. With Polar Expres now operating as part of our growing CRYOPDP operations, we are confident this acquisition will provide us with additional growth in the EMEA region.”

 

About CRYOPDP

One of the top leaders in its field, CRYOPDP aims to improve the health of people around the world by providing global innovative temperature-controlled logistics solutions to the Clinical Research and Cell & Gene Therapy Communities. CRYOPDP has facilities in 15 countries and conducts business  in more than 150 countries. 

 

About Cryoport, Inc.

Cryoport, Inc. (Nasdaq: CYRX) is redefining logistics for the life sciences industry by providing a platform of temperature-controlled supply chain solutions, serving the Biopharma, Reproductive Medicine, and Animal Health markets.  Their mission is to support life and health on earth by providing reliable and comprehensive solutions for the life sciences industry through advanced technologies, global supply chain network and dedicated scientists, technicians and supporting team of professionals.